Hope to start supply of ZyCoV-D vaccine by mid to end Sept: Zydus Group
New Delhi, Aug 21 (PTI):
Drug firm Zydus Cadila on Saturday said it is looking to supply its COVID-19 vaccine ZyCoV-D by the middle to end of September, adding the pricing of the dose will be announced in the next one or two weeks.
The company’s indigenously developed needle-free three-dose COVID-19 vaccine ZyCoV-D was granted emergency use authorisation (EUA) by the drug regulator on Friday, making it the first vaccine to be administered to beneficiaries in the age group of 12-18 years in the country.
“Post the emergency use authorisation, now we will work closely with the regulatory authorities to work on the pricing and modality of delivery of the doses of our vaccine. In next one or two weeks we will have better clarity on the pricing,” Zydus Group Managing Director Sharvil Patel said in a virtual press conference.
The company hopes that “by middle to end of September, we can start supplying the vaccines, and as I said we need to scale up to 1 crore doses and we believe by October we can achieve this. We believe by October we will start producing 1 crore doses and that would mean by end of Jan we can have 4 to 5 crore doses,” he added.
Asked if the company was considering partnering with other firms to scale up production of its vaccine, Patel said Zydus Cadila is actively looking at ramping up manufacturing both domestically through partnerships and also outside of the country.
The company is also seeking approval for a two-dose regimen of the vaccine, he added.
Describing the approval for Zydus Cadila’s vaccine as a momentous feat, Prime Minister Narendra Modi in a tweet on Friday had said, “India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ”ZyCov-D” vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed.”
ZyCoV-D is the sixth vaccine to get the emergency use authorisation in the country, after Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russian vaccine Sputnik V and the vaccines of Moderna and Johnson and Johnson.
